RAGE antagonist peptide
| Code | Size | Price |
|---|
| TAR-TP1935-1mg | 1mg | £148.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Documents
Further Information
Bioactivity:
Receptor for advanced glycation end products (RAGE) antagonist. Blocks S100P, S100A4 and HMGB-1 mediated RAGE activation in vitro and in vivo. Inhibits growth and metastasis of rat glioma tumors. Reduces cell growth and RAGE-mediated NF-κB activity in human PDAC cell lines. Inhibits effects of TDI exposure in BALB/c mice.
CAS:
1092460-91-7
Formula:
C57H101N13O17S
Molecular Weight:
1272.56
Purity:
0.98
SMILES:
0
References
Arumugam et al (2012) S100P-derived RAGE antagonistic peptide reduces tumor growth and metastasis. Clin.Cancer.Res. 18 4356 PMID:
Yao et al (2016) The receptor for advanced glycation end products is required for beta -catenin stabilization in a chemical-induced asthma model. Br.J.Pharmacol. 173 2600 PMID: